Simultaneous tumor and stroma targeting by oncolytic viruses

Anne Everts, Melissa Bergeman, Grant McFadden, Vera Kemp

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations


Current cancer therapeutics often insufficiently eradicate malignant cells due to the surrounding dense tumor stroma. This multi-componential tissue consists of mainly cancer-associated fibroblasts, the (compact) extracellular matrix, tumor vasculature, and tumor-associated macrophages, which all exert crucial roles in maintaining a pro-tumoral niche. Their continuous complex interactions with tumor cells promote tumor progression and metastasis, emphasizing the challenges in tumor therapy development. Over the last decade, advances in oncolytic virotherapy have shown that oncolytic viruses (OVs) are a promising multi-faceted therapeutic platform for simultaneous tumor and stroma targeting. In addition to promoting tumor cell oncolysis and systemic anti-tumor immunity, accumulating data suggest that OVs can also directly target stromal components, facilitating OV replication and spread, as well as promoting anti-tumor activity. This review provides a comprehensive overview of the interactions between native and genetically modified OVs and the different targetable tumor stromal components, and outlines strategies to improve stroma targeting by OVs.

Original languageEnglish (US)
Article number474
Pages (from-to)1-20
Number of pages20
Issue number11
StatePublished - Nov 2020


  • Oncolytic viruses
  • Tumor microenvironment
  • Tumor stroma
  • Virotherapy

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Simultaneous tumor and stroma targeting by oncolytic viruses'. Together they form a unique fingerprint.

Cite this